Literature DB >> 9070440

Inactive conformation of an insulin despite its wild-type sequence.

G Kurapkat1, E De Wolf, J Grötzinger, A Wollmer.   

Abstract

The peptide group between residues B24 and B25 of insulin was replaced by an ester bond. This modification only in the backbone was meant to eliminate a structurally important H-bond between the amide proton of B25 and the carbonyl oxygen of A19, and consequently to enhance detachment of the C-terminal B-chain from the body of the molecule, exposing the underlying A-chain. According to a model derived from the effects of side-chain substitutions, main-chain shortening, and crosslinking, this conformational change is prerequisite for receptor binding. Contrary to the expectation that increased flexibility would increase receptor binding and activity, depsi-insulin ([B24-B25 CO-O]insulin) has turned out be only 3-4% potent. In search of an explanation for this observation, the solution structure of depsi-insulin was determined by two-dimensional 1H-NMR spectroscopy. It was found that the loss of the B25-A19 H-bond does not entail detachment of the C-terminal B-chain. On the contrary, it is overcompensated by a gain in hydrophobic interaction achieved by insertion of the Phe B25 side chain into the molecule's core. This is possible because of increased rotational freedom in the backbone owing to the ester bond. Distortion of the B20-B23 turn and an altered direction of the distal B-chain are consequences that also affect self-association. The exceptional position of the B25 side chain is thus the key feature of the depsi-insulin structure. Being buried in the interior, it is not available for guiding the interaction with the receptor, a crucial role attributed to it by the model. This seems to be the main reason why the structure of depsi-insulin represents an inactive conformation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9070440      PMCID: PMC2143665          DOI: 10.1002/pro.5560060307

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  39 in total

Review 1.  Protein structures from NMR.

Authors:  R Kaptein; R Boelens; R M Scheek; W F van Gunsteren
Journal:  Biochemistry       Date:  1988-07-26       Impact factor: 3.162

2.  The effect of a non-peptide interchain crosslink on the reoxidation of reduced insulin.

Authors:  D Brandenburg; A Wollmer
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1973-06

3.  The structure of 2Zn pig insulin crystals at 1.5 A resolution.

Authors:  E N Baker; T L Blundell; J F Cutfield; S M Cutfield; E J Dodson; G G Dodson; D M Hodgkin; R E Hubbard; N W Isaacs; C D Reynolds
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1988-07-06       Impact factor: 6.237

4.  The relation of conformation and association of insulin to receptor binding; x-ray and circular-dichroism studies on bovine and hystricomorph insulins.

Authors:  S P Wood; T L Blundell; A Wollmer; N R Lazarus; R W Neville
Journal:  Eur J Biochem       Date:  1975-07-15

5.  Implications of replacing peptide bonds in the COOH-terminal B chain domain of insulin by the psi (CH2-NH) linker.

Authors:  S H Nakagawa; N L Johansen; K Madsen; T W Schwartz; H S Tager
Journal:  Int J Pept Protein Res       Date:  1993-12

6.  Role of the COOH-terminal B-chain domain in insulin-receptor interactions. Identification of perturbations involving the insulin mainchain.

Authors:  S H Nakagawa; H S Tager
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

7.  Single chain des-(B30) insulin. Intramolecular crosslinking of insulin by trypsin catalyzed transpeptidation.

Authors:  J Markussen; K H Jørgensen; A R Sørensen; L Thim
Journal:  Int J Pept Protein Res       Date:  1985-07

8.  Importance of the character and configuration of residues B24, B25, and B26 in insulin-receptor interactions.

Authors:  R G Mirmira; S H Nakagawa; H S Tager
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

9.  Intramolecular cross-linking of insulin. Preparation and properties of oxalyl- and malonyl-bis(methionyl) insulin.

Authors:  B R Srinivasa; F H Carpenter
Journal:  Int J Pept Protein Res       Date:  1983-08

10.  Nonlocal structural perturbations in a mutant human insulin: sequential resonance assignment and 13C-isotope-aided 2D-NMR studies of [PheB24-->Gly]insulin with implications for receptor recognition.

Authors:  Q X Hua; S E Shoelson; M A Weiss
Journal:  Biochemistry       Date:  1992-12-01       Impact factor: 3.162

View more
  6 in total

1.  A cavity-forming mutation in insulin induces segmental unfolding of a surrounding alpha-helix.

Authors:  Bin Xu; Qing-Xin Hua; Satoe H Nakagawa; Wenhua Jia; Ying-Chi Chu; Panayotis G Katsoyannis; Michael A Weiss
Journal:  Protein Sci       Date:  2002-01       Impact factor: 6.725

Review 2.  Insulin: a small protein with a long journey.

Authors:  Qingxin Hua
Journal:  Protein Cell       Date:  2010-06       Impact factor: 14.870

3.  The solution structure of a superpotent B-chain-shortened single-replacement insulin analogue.

Authors:  G Kurapkat; M Siedentop; H G Gattner; M Hagelstein; D Brandenburg; J Grötzinger; A Wollmer
Journal:  Protein Sci       Date:  1999-03       Impact factor: 6.725

4.  Chiral mutagenesis of insulin. Foldability and function are inversely regulated by a stereospecific switch in the B chain.

Authors:  Satoe H Nakagawa; Ming Zhao; Qing-xin Hua; Shi-Quan Hu; Zhu-li Wan; Wenhua Jia; Michael A Weiss
Journal:  Biochemistry       Date:  2005-04-05       Impact factor: 3.162

5.  The use of phage display to distinguish insulin autoantibody (IAA) from insulin antibody (IA) idiotypes.

Authors:  D Devendra; T S Galloway; S J Horton; A Evenden; U Keller; T J Wilkin
Journal:  Diabetologia       Date:  2003-06-03       Impact factor: 10.122

6.  Structural and functional study of the GlnB22-insulin mutant responsible for maturity-onset diabetes of the young.

Authors:  Květoslava Křížková; Václav Veverka; Lenka Maletínská; Rozálie Hexnerová; Andrzej M Brzozowski; Jiří Jiráček; Lenka Žáková
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.